0O8G.L - MDxHealth SA

LSE - LSE Prezzo differito. Valuta in EUR.
0,3790
-0,0050 (-1,30%)
Al 02:30PM BST. Mercato aperto.
Il grafico dei titoli non è supportato dal tuo browser attuale
Chiusura precedente0,3840
Aperto0,3910
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno0,3790 - 0,3910
Intervallo di 52 settimane0,2600 - 0,8690
Volume7.120
Media Volume68.467
Capitalizzazione209.552
Beta (5 anni mensile)0,86
Rapporto PE (ttm)N/D
EPS (ttm)-0,2150
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    MDxHealth Announces its Extraordinary General Shareholders’ Meeting

    NEWS RELEASE – REGULATED INFORMATION JUNE 5, 2023, 5:30 pm ET/ 23:30 CEST MDxHealth Announces its Extraordinary General Shareholders’ Meeting IRVINE, CA, and HERSTAL, BELGIUM – June 5, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today invites the holders of securities issued by the Company to its extraordinary general shareholders' meeting that will be held on Friday, June 30, 2023 at 9:00 a.m., Belgia

  • GlobeNewswire

    MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings

    NEWS RELEASE - REGULATED INFORMATION 25 May 2023, 22:30 CET MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings IRVINE, CA, and HERSTAL, BELGIUM – 25 May 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) ("MDxHealth" or the "Company"), a commercial-stage precision diagnostics company, today held its ordinary annual general shareholders' meeting ("AGM") and an extraordinary general shareholders' meeting ("EGM"). The items on the agenda of the AGM incl

  • GlobeNewswire

    MDxHealth to Present at the 43rd Annual William Blair Growth Stock Conference

    NEWS RELEASEMay 23, 2023, 4PM ET/ 22:00 CET MDxHealth to Present at the 43rd Annual William Blair Growth Stock Conference IRVINE, CA, and HERSTAL, BELGIUM – May 23, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH), a commercial-stage precision diagnostics company, today announced that Michael McGarrity, Chief Executive Officer, will present at William Blair’s 43rd Annual Growth Stock Conference on Thursday, June 8, 2023, at 1:00pm ET. A live webcast of the presentation will be available

  • GlobeNewswire

    MDxHealth Reports Q1-2023 Results

    NEWS RELEASE - REGULATED INFORMATION15 MAY 2023, 4:00PM EDT / 22:00 CET MDxHealth Reports Q1-2023 Results Year-over-year revenues increase by 141% to $14.7 million; excluding GPS, revenues up 39% Gross margin expanded by 1,270 basis points over prior year periodPositive Local Coverage Determination (LCD), extending coverage for Select mdx test to Medicare population IRVINE, CA, and HERSTAL, BELGIUM – May 15, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics co

  • GlobeNewswire

    MDxHealth to Present First Quarter 2023 Financial Results on May 15

    NEWS RELEASE 1 MAY 2023, 4PM ET / 22:00 CET MDxHealth to Present First Quarter 2023 Financial Results on May 15 Company to Host Conference Call with Live Q&A, May 15, 2023 at 4:30pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 1, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2023, after market close on Monday, May 15, 2023. Title:MDxHealth Presents

  • GlobeNewswire

    MDxHealth Announces its Ordinary and Extraordinary General Shareholders’ Meetings

    NEWS RELEASE – REGULATED INFORMATIONAPRIL 25, 2023, 4:00 pm ET/ 22:00 CET IRVINE, CA, and HERSTAL, BELGIUM – April 25, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today invites the holders of securities issued by the Company to its ordinary and extraordinary general shareholders' meetings that will be held on Thursday, May 25, 2023 at 3:00 p.m., Belgian time. The items on the agenda of the ordinary and

  • GlobeNewswire

    Foundational LCD Covers Select mdx for Prostate Cancer

    NEWS RELEASE – INSIDE INFORMATIONApril 19, 2023, 4:00PM EDT / 22:00 CET IRVINE, CA, and HERSTAL, BELGIUM – April 19, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, received notice that its Select mdx for Prostate Cancer test has successfully completed a rigorous technical assessment process with the Molecular Diagnostics Services (MolDX) Program developed by Palmetto GBA. Select mdx will be reimbursed throughout the U.S. for Medicare patients who m

  • GlobeNewswire

    MDxHealth Shareholder Transparency Declaration

    NEWS RELEASE – REGULATED INFORMATION APRIL 7, 2023, 4:30 pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – April 7, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, announces today in accordance with Article 14 of the Belgian Act of May 2, 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the

  • GlobeNewswire

    MDxHealth Confirms No Exposure to Silicon Valley Bank or Silvergate Bank

    NEWS RELEASE 13 MARCH 2023, 2:00 AM ET / 08:00 CET IRVINE, CA, and HERSTAL, BELGIUM – March 13, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today confirms that neither MDxHealth SA, nor any of its subsidiaries, have any exposure to Silicon Valley Bank (“SVB”) or Silvergate Bank. About mdxhealth Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatme

  • GlobeNewswire

    MDxHealth Announces Update of Outstanding Shares and Voting Rights

    NEWS RELEASE – REGULATED INFORMATIONMARCH 8, 2023, 5:00 pm ET/ 23:00 CET IRVINE, CA, and HERSTAL, BELGIUM – March 8, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced, in accordance with Article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, that in the context o

  • GlobeNewswire

    MDxHealth Reports Financial Year 2022 Results and Provides Business Update and Outlook for 2023

    NEWS RELEASE - REGULATED INFORMATION8 MARCH 2023, 4:00 PM EST / 22:00 CET Conference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – March 8, 2023 – MDxHealth SA (NASDAQ/Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced its financial results for the fourth quarter and year ended December 31, 2022, and provided a business update and outlook for 2023. Highlights for the fourth quarter and yea

  • GlobeNewswire

    MDxHealth Announces Exercise of Option

    NEWS RELEASE – REGULATED INFORMATION MARCH 6, 2023, 5:30 pm ET/ 23:30 CET IRVINE, CA, and HERSTAL, BELGIUM – March 6, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced that, in the context of the registered public offering of 10,000,000 American Depositary Shares (“ADSs”) (each representing 10 ordinary shares of the Company without nominal value) previously announced and completed on February 7, 2023 (the

  • GlobeNewswire

    MDxHealth Shareholder Transparency Declarations

    NEWS RELEASE – REGULATED INFORMATION MARCH 3, 2023, 4:30 pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – March 3, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, announces today in accordance with Article 14 of the Belgian Act of 2 May 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the "

  • GlobeNewswire

    MDxHealth to Participate in 43rd Annual Cowen Healthcare Conference

    NEWS RELEASEFEBRUARY 28, 2023, 4:30 pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 28, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH), a commercial-stage precision diagnostics company, today announced that Michael McGarrity, chief executive officer, will present at Cowen’s 43rd Annual Health Care Conference on Monday, March 6th, 2023 at 1:30pm ET. A live webcast of the presentation will be available on the Company’s website. Cowen’s 43rd Annual Health Care Conference is t

  • GlobeNewswire

    MDxHealth to Present Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023

    NEWS RELEASEFEBRUARY 22, 2023, 4:30pm ET/ 22:30 CET Company to Host Conference Call with Live Q&A, March 8, 2023 at 4:30pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 22, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2022, after market close on Wednesday, March 8, 2023. Title:Mdxhea

  • GlobeNewswire

    MDxHealth Announces Update of Outstanding Shares and Voting Rights and Update of Financial Calendar

    NEWS RELEASE – REGULATED INFORMATIONFEBRUARY 15, 2023, 4:30 pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 15, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced, in accordance with Article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, that in the c

  • GlobeNewswire

    MDxHealth Announces UnitedHealthcare to Provide Commercial Coverage for the Genomic Prostate Score (GPS) Test

    NEWS RELEASE 13 FEBRUARY 2023, 4:00PM ET / 22:00 CET UnitedHealthcare singles out mdxheath’s GPS test as its only commercially-covered test to risk stratify men newly diagnosed with localized prostate cancer IRVINE, CA, and HERSTAL, BELGIUM – February 13, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced that UnitedHealthcare will cover the mdxhealth Genomic Prostate Score (GPS) test (formerly Oncotype DX GPS) under UnitedHealthcare’s

  • GlobeNewswire

    MDxHealth Announces Pricing of Offering of ADSs in the United States

    NEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATIONFEBRUARY 3, 2023, 8:00 am ET/ 14:00 CET MDxHealth Announces Pricing of Offering of ADSsin the United States IRVINE, CA, and HERSTAL, BELGIUM – February 3, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced that it has priced a registered public offering of 10,000,000 American Depositary Shares (“ADSs”) (each representing 10 ordinary shares of the Compan

  • GlobeNewswire

    MDxHealth Announces Launch of Offering of ADSs in the United States

    NEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATIONFEBRUARY 1, 2023, 4PM ET/ 22:00 CET MDxHealth Announces Launch of Offering of ADSs in the United States IRVINE, CA, and HERSTAL, BELGIUM –February 1, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, announced the launch of a proposed offering of $40,000,000 of American Depositary Shares ("ADSs") (each representing 10 ordinary shares of the Company without nominal val

  • GlobeNewswire

    MDxHealth Provides Updated and Supplemental Financial Information Related to Acquisition of GPS Test

    NEWS RELEASE –REGULATED INFORMATION20 JANUARY 2023, 1:00 am ET / 7:00 am CET MDxHealth Provides Updated and Supplemental Financial Information Related to Acquisition of GPS Test IRVINE, CA, and HERSTAL, BELGIUM – January 20, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today provided supplemental information related to its acquisition of the Oncotype DX® GPS (Genomic Prostate Score®) test on August 2, 2022 (the “GPS Test Acquisition”), from Genom

  • GlobeNewswire

    MDxHealth Reports Preliminary 2022 Revenues and Reaffirms 2023 Revenue Guidance

    NEWS RELEASE – INSIDE AND REGULATED INFORMATION9 JANUARY 2023, 4PM ET / 22:00 CET MDxHealth Reports Preliminary 2022 Revenues and Reaffirms 2023 Revenue Guidance IRVINE, CA, and HERSTAL, BELGIUM – January 9, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today reported preliminary 2022 revenues and reaffirmed its 2023 revenue guidance. The Company expects to report 2022 revenues of approximately $37 million, with a year-end cash balance of $15.5 mi

  • GlobeNewswire

    Mdxhealth files U.S. Shelf Registration on Form F-3

    NEWS RELEASE – REGULATED INFORMATIONDecember 19, 2022, 5:00PM EDT / 23:00 CET Mdxhealth files U.S. Shelf Registration on Form F-3 IRVINE, CA, and HERSTAL, BELGIUM – December 19, 2022 – Mdxhealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced that it has filed a U.S. “shelf” registration statement for its American Depositary Shares (“ADSs”), each representing 10 ordinary shares. The Company filed the shelf registration statement and associated financ

  • GlobeNewswire

    MDxHealth Provides Business Update

    NEWS RELEASE – INSIDE AND REGULATED INFORMATION29 NOVEMBER 2022, 4:00PM EDT / 22:00 CET MDxHealth Provides Business Update IRVINE, CA, and HERSTAL, BELGIUM – November 29, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today provided clinical and reimbursement product developments, updated guidance for 2022, and initial guidance for 2023. Select mdx reimbursement update Under the foundational LCD (Local Coverage Decision) process recently implemente

  • GlobeNewswire

    MDxHealth Reports Q3-2022 Results

    NEWS RELEASE - REGULATED INFORMATION27 OCTOBER 2022, 4:00PM EDT / 22:00 CET MDxHealth Reports Q3-2022 Results IRVINE, CA, and HERSTAL, BELGIUM – October 27, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced its financial results for the third quarter ended September 30, 2022. Michael K. McGarrity, CEO of mdxhealth, commented: “We are pleased to report continued strong operating results for the third quarter 2022. Our focus on operating

  • GlobeNewswire

    MDxHealth Reports Half Year 2022 Results

    NEWS RELEASE - REGULATED INFORMATION25 AUGUST 2022, 4:00PM EDT, 22:00 CET MDxHealth Reports Half Year 2022 Results IRVINE, CA, and HERSTAL, BELGIUM – August 25, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH) ("mdxhealth" or the "Company"), a commercial-stage precision diagnostics company, today announced its financial results for the half year ended June 30, 2022. Michael K. McGarrity, CEO of mdxhealth, commented: “We are excited to report strong operating results for the first half of 2022, couple